Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-92.01	-116.05	-133.82	-121.76	-79	-36.17
Depreciation & Amortization	3.78	2.34	2.37	2.97	3.33	3.64
Loss (Gain) From Sale of Assets	0.02	0.02	0.15	-	-	-
Loss (Gain) From Sale of Investments	0.26	-1.14	-2.93	0.33	-1.91	-3.27
Stock-Based Compensation	22.25	26.8	28.22	26.97	20.99	19.58
Other Operating Activities	-1.17	2.14	-5.17	-0.08	0.28	10.41
Change in Accounts Receivable	-0.16	1.97	11.7	3.26	-0.08	27.82
Change in Accounts Payable	-2.13	-0.41	-1.15	-4.63	3.77	-0.88
Change in Income Taxes	32.43	-1	-2.29	8.54	-24.21	-4.13
Change in Other Net Operating Assets	13.54	6.57	-0.24	-0.37	6.84	-9.91
Operating Cash Flow	-23.18	-78.76	-103.15	-84.78	-70	7.09
Operating Cash Flow Growth	-	-	-	-	-	-90.08%
Capital Expenditures	-20.39	-17.95	-9.06	-2.13	-0.75	-1.45
Investment in Securities	77.51	76.18	-44.52	57.02	37.74	21.28
Investing Cash Flow	57.12	58.24	-53.58	54.9	36.99	19.83
Issuance of Common Stock	0.16	0.15	2.21	21.26	3.61	10.48
Other Financing Activities	-25.67	-27.77	195.92	-1.23	-0.53	-1.5
Financing Cash Flow	-25.51	-27.63	198.13	20.03	3.08	8.98
Net Cash Flow	8.43	-48.16	41.39	-9.85	-29.93	35.9
Free Cash Flow	-43.57	-96.71	-112.21	-86.91	-70.75	5.64
Free Cash Flow Growth	-	-	-	-	-	-91.45%
Free Cash Flow Margin	-67.23%	-142.99%	-141.67%	-100.87%	-72.88%	4.61%
Free Cash Flow Per Share	-2.05	-4.57	-5.35	-4.22	-3.51	0.28
Cash Interest Paid	9.71	11.71	1.99	-	-	-
Cash Income Tax Paid	-	0.24	4.9	-	0.03	0.11
Levered Free Cash Flow	-30.99	-71.38	-62.34	-42.08	-57.67	9.55
Unlevered Free Cash Flow	-26.07	-64.55	-59.13	-42.08	-57.67	9.55
Change in Working Capital	43.69	7.13	8.02	6.79	-13.69	12.9

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q